ESMO 2016 Press Release: High response rate in phase I/II paediatric brain cancer trial sets stage for combination therapy with higher response and lower toxicity

LUGANO-COPENHAGEN – A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen.

“The likelihood of curing a child with a low-grade glioma is very high,” said lead author Dr Mark Kieran, Director, Paediatric Medical Neuro-Oncology, Dana-Farber Boston Children’s, Boston, US. “In fact many children don’t suffer lifelong from the tumour but rather from the cognitive damage and secondary malignancies caused by radiation therapy.”

He continued: “The development of drugs that target the specific causative mutation of the tumour and avoid long-term toxicities may revolutionise the treatment of paediatric brain cancer.”

Up to 10% of paediatric low-grade gliomas have the BRAF V600 mutation. Today researchers reported the phase I and phase II trial results of dabrafenib, a selective inhibitor of mutant protein. The study included 32 patients aged one to 16 years with BRAF V600-mutant low-grade glioma, of whom 15 participated in the phase I trial and 17 were in the phase II trial.

The phase I trial, which focused on determining the recommended phase II dose, did not find any significant dose-limiting toxicities. The recommended dose was therefore based on the pharmacokinetic activity of the drug and was set at 4.5 mg/kg/day for patients aged 12 years and older and 5.25 mg/kg/day for patients under the age of 12.

The phase II trial assessed toxicities with dabrafenib, and whether it could stop tumours from growing or cause them to shrink. “Paediatric low-grade gliomas are a little bit unique in that patients can survive their entire life with a tumour that stops growing, unlike other cancers which need to be completely removed,” said Kieran.

The objective response rate was 72%, with 23 out of 32 patients responding to the drug. In two patients the tumour disappeared and in 11 patients the tumour shrunk by more than half – of these 13 patients eight are still on the therapy. Thirteen patients had stable disease of at least six months’ duration, and 11 of them are still on the therapy.

Regarding adverse events, there were no cases of squamous cell carcinoma, which has been observed in previous trials of dabrafenib in adults with BRAF V600E positive tumours, most of whom have melanoma. One patient had an allergic reaction to the drug. Minor side effects were similar to those seen in adults, including transient fever, upset stomach, fatigue and skin rash.

Studies in adults with BRAF V600E mutations have shown that combining a BRAF inhibitor with a MEK inhibitor reduces toxicity and produces more activity for a longer period of time. The encouraging results with dabrafenib in children have provided the impetus for phase I and II trials with a MEK inhibitor to determine the dose and toxicities, and a trial combining the two drugs is now underway.

Kieran said: “We want to make the response rate with dabrafenib even higher by combining it with a MEK inhibitor since that works in adults. Adding two drugs together normally produces twice as much toxicity. But much of the toxicity from the BRAF drug is inhibited by the MEK drug, so the combination is less toxic than either drug alone, which is unusual.”

Kieran concluded: “The finding that dabrafenib can shrink tumours or stop them growing is exciting and has led to trials with a MEK inhibitor and now the combination of drugs. This combined therapy may completely change the way we treat low-grade gliomas in children with this mutation. The caveat is that these targeted personalised drugs are relatively new so we need to make sure that they don’t have any long-term developmental toxicities in children.”

Commenting on the findings, Professor Michael Weller, chairman, Department of Neurology, University Hospital Zurich, Switzerland, said: “The encouraging thing about this study is that this targeted treatment seems to work. At the moment in neuro-oncology we know almost everything about the molecular make-up of gliomas in adults and in children but we have not really been able to translate all this knowledge into an effective therapeutic agent.”

“These findings will have implications for clinical practice because many parents are willing to travel all around the world to get access to a promising treatment,” he continued. “We have almost no randomised data for brain tumours in children, at least for gliomas, because the tumours are too rare and the trials are difficult for ethical reasons.”

Weller concluded: “We need longer follow up to find out how long the responses last and whether we get long-term survival. And then of course in children we want to know if there is any long-term toxicity.”

-END- 

Notes to Editors

References

Abstract LBA19_PR “The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas” will be presented by Dr Mark Kieran during the Proffered Paper Session, CNS tumours, on Friday, 7 October 2016, 16:00 to 17:30 (CEST) in Room Bern.

Disclaimer

This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO and ESMO cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology

ESMO is the leading professional organisation for medical oncology. Comprising more than 13,000 oncology professionals from over 130 countries, we are the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Founded in 1975, ESMO has European roots and a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience. Our educational and information resources support an integrated, multi-professional approach to cancer treatment. We seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

Abstract for LBA19_PR

The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas

M.W. Kieran1, E. Bouffet2, U. Tabori3, A. Broniscer4, K. Cohen5, J. Hansford6, B. Geoerger7, P. Hingorani8, I. Dunkel9, M. Russo10, L. Tseng10, Q. Liu10, N. Nebot10, J. Whitlock2, D. Hargrave11
1. Pediatric Medical Neuro-Oncology, Harvard Medical School, Boston Children’s Hospital, Dana-Farber Cancer Institute, Boston, MA, USA, 2. Haematology/Oncology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 3. Division of Haematology/Oncology, Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 4. Oncology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA, 5. Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, 6. Children's Cancer Centre, The Royal Children’s Hospital, University of Melbourne, Murdoch Children’s Research Institute, Melbourne, Australia, 7. Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France, 8. Hematology/Oncology, Phoenix Children’s Hospital, Phoenix, AZ, USA, 9. Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 10. Global Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 11. Haematology and Oncology, Great Ormond Street Hospital, London, UK

Background: BRAF V600 mutations are present in 15%-20% patients (pts) with pediatric low-grade gliomas (pLGG). Relative to pts with BRAF V600–wild type pLGG, pts with BRAF V600E–mutant pLGG had poor survival and lower objective response rates (ORR) to initial (29%) and 2nd-line (11%) chemotherapy (Lassaletta A, ASCO 2016). There remains a need for improved treatment options for this pLGG subgroup. Dabrafenib is a potent and selective inhibitor of the V600–mutant form of the BRAF kinase. We report the results of the first study of dabrafenib in pediatric pts with BRAF V600–mutant recurrent or progressive LGG.

Methods: Thirty-two pts aged 2-17 y with BRAF V600–mutant relapsed or refractory LGG were enrolled Dec 2013 to Jul 2015 across 4 dose levels of dabrafenib monotherapy up to and including the recommended phase 2 dose (RP2D; 4.5 mg/kg/day in pts ≥ 12 y, 5.25 mg/kg/day in pts < 12 y, divided into 2 equal doses per day [Kieran MW, ASCO 2015]). The results presented are from all 32 pts with pLGG (15 pts enrolled into the dose-finding and 17 pts treated after determination of the RP2D). Overall, 24 pts were treated at the RP2D.

Results: Twenty-two of the 32 pts remained on study as of April 2016. Adverse events were generally similar to those observed in adults, with frequent low-grade pyrexia, vomiting, fatigue, headache and rash. There have been no reports of cutaneous squamous cell carcinoma. The most frequent grade 3 or 4 AE was pneumonia, in 3 pts. 1 pt experienced a significant allergic reaction on day 2 of dosing and again upon rechallenge and was discontinued from study. Independent confirmed overall response by RANO criteria was 2 CRs and 11 PRs in this 2nd-line setting (N=32, ORR 41% [95% CI, 24%-59%]), with a median duration of response of 11 months (8 responders ongoing). There were an additional 13 pts (41%) with SD of 6 months or greater duration (11 ongoing). Investigator confirmed overall response was 1 CR and 22 PRs (ORR 72% [95% CI, 53%-86%]).

Conclusions: Targeted therapy using dabrafenib showed promising activity, with an independently confirmed ORR of 41%, and was well tolerated in this population with recurrent or progressive BRAF V600–mutant pLGG, comparing favorably to historical data.

Clinical trial identification: Regulatory Agency Identifying Number(s): IND No.: 117,989. EudraCT Number: 2012-001499-12. Release date: 24 July, 2012.

Legal entity responsible for the study: Supported by GlaxoSmithKline. Dabrafenib is an asset of Novartis AG as of 2 March 2015.

Funding: Supported by GlaxoSmithKline. Dabrafenib is an asset of Novartis AG as of 2 March 2015.

Disclosure:
M.W. Kieran: Membership on Board of Directors or Advisory Committee: Novartis.
E. Bouffet, D. Hargrave: Consultancy: Novartis.
A. Broniscer, K. Cohen, J. Whitlock: Research Funding: Novartis.
I. Dunkel: Consultancy: Bayer, BMS, Eisai, Pfizer.
M. Russo: Employment: Novartis Equity Ownership: Novartis, GSK.
L. Tseng: Employment: Novartis Pharmaceuticals.
Q. Liu: Employment: Novartis Equity Ownership: Novartis.
N. Nebot: Employment: Novartis.
All other authors have declared no conflicts of interest.

Keywords: pediatric cancer, BRAF, dabrafenib, low grade glioma